BACLOFEN FOR REDUCTION OF CRAVING AND ANXIETY DEPRESSION IN ALCOHOL DEPENDENCE SYNDROME: A PRELIMINARY INVESTIGATION
Abstract
Introduction Alcohol dependence affects nearly 10% of the population, both in the USA and in Europe, and poses serious threat to public health by increasing morbidity & mortality. Treatment for alcohol dependence consists of psychological, social and pharmaceutical interventions. The ability of baclofen to reduce alcohol craving and promote alcohol abstinence in alcohol-dependent individuals has been observed in some open-label studies.
Materials and method Thirteen patients (12 male & 1 female) who were self referred were taken from de-addiction clinic of I.M.S, B.H.U. All patients were assessed for eligibility and were consequently admitted. Thirteen patients (12 male & 1 female) were taken from de-addiction clinic of I.M.S, B.H.U. All patients were admitted. The following tools were administered: Hamilton’s anxiety; Hamilton’s depression scale; Penn craving scale; Emergent Side effects Semi-structured interview; Abstinence Semi-structured interview. All patients were assessed on baseline using semi-structured proforma and relevant history. It was 12 week long follow up study. Patients were assessed on baseline and at 2, 4, 6, 8, 10 and 12 weeks.
Results Out of 13 patients enrolled, 2 patients dropped at 1st follow up, only 11 patients completed the (10 male ,1 female) study. Out of 11 patients, 9 patients (8 males and 1 female) reported complete abstinence and 2 male patients had significant reduction in craving, but continued minimal intake of alcohol. Also there was a declining trend in cumulative abstinence as measured by number of standard drinks/day. Treatment adherence was 85%.
Discussion Total abstinence was present in 8 patients. In the present study the beneficial effect of baclofen in maintaining abstinence has been attributed to its capacity to reduce anxiety, this study also hypothesized that baclofen may also have an antidepressant effect on alcohol-abstinent participants. Also the GABA action of baclofen is beneficial.
Conclusion Drug was found to be cost effective as well safe for use on an out-patient basis.
References
I. U.S. Department of Health and Human Services (2000) 10th Special Report to the U.S. Congress on Alcohol and Health. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism
II. https://pubs.niaaa.nih.gov/publications/social/module1epidemiology/module1.html
III. Bennett, L. A., Janca, A., Grant, B. F. & Sartorius, N. (1993) Boundaries between normal and pathological drinking: a cross-cultural comparison. Alcohol Health and Research World , 17 , 190–195
IV. Ray, R., Mondal, A. B., Gupta, K., Chatterjee, A. & Bajaj, P. (2004) The Extent, Pattern and Trends of Drug Abuse in India: National Survey. New Delhi: United Nations Office on Drugs and Crimes and Ministry of Social Justice and Empowerment, Government of India
V. Isaac, M. (1998) India. In: Grant, M., ed. Alcohol and Emerging Markets: Patterns, Problems and Responses , pp. 145–175. Philadelphia: Brunner/Mazel.
VI. Benegal, V., Nayak, M., Murthy, P., Chandra, P. & Gururaj, G. (in press) Women and alcohol use in India. In: Obot, I. & Room, R., eds. Gender, Alcohol and Culture in Low Income Countries . Geneva: World Health Organization.
VII. World Health Organization (WHO). Global Status Report on Alcohol and Health. p. XIV. 2014 ed. Available at: http://www.who.int/substance_abuse/publications/global_alcohol_report/msb_gsr_2014_1.pdf?ua=1(link is external). Accessed 1/18/17)
VIII. World Health Organization (WHO). Global Status Report on Alcohol and Health. p. XIII. 2014 ed. Available at: http://www.who.int/substance_abuse/publications/global_alcohol_report/msb_gsr_2014_1.pdf?ua=1(link is external). Accessed 1/18/17
IX. Swift RM, Leggio L. (2009) Adjunctive pharmacotherapy in the treatment of alcohol and drug dependence. In Miller P (ed). Evidence-Based Addiction Treatment, Part III, Chapter 17. Amsterdam, The Netherlands: Elsevier, 287–310.
X. Addolorato G, Abenavoli L, Leggio L et al. (2005) How many cravings? Pharmacological aspects of craving treatment in alcohol addiction: a review. Neuropsychobiology 51:59–66.
XI. Addolorato G, Caputo F, Capristo E et al. (2000) Ability of baclofen in reducing alcohol craving and intake: II-preliminary clinical evidence. Alcohol Clin Exp Res 24:67–71.
XII. Flannery BA, Garbutt JC, Cody M et al. (2004) Baclofen for alcohol dependence: a preliminary open-label study. Alcohol Clin Exp Res 28:1517–23.
XIII. Ameisen, 2005; Bucknam, 2007).( Ameisen O. (2005) Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician. Alcohol Alcohol 40:147–50.
XIV. Bucknam W. (2007) Suppression of symptoms of alcohol dependence and craving using high-dose baclofen. Alcohol Alcohol 42:158–60.
XV. Kahn R, Biswas K, Childress AR et al. (2009) Multi-center trial of baclofen for abstinence initiation in severe cocaine-dependent individuals. Drug Alcohol Depend 103:59–64.
XVI. Shoptaw S, Yang X, Rotheram-Fuller EJ et al. (2003) Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. J Clin Psychiatry 64:1440–8.
XVII. Giovanni Addolorato1, Lorenzo Leggio, Anna Ferrulli, Silvia Cardone, Giorgio Bedogni, Fabio Caputo, Giovanni Gasbarrini, Raffaele Landolfi and the Baclofen Study Group Dose–Response Effect of Baclofen in Reducing Daily Alcohol Intake in Alcohol Dependence: Secondary Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial Alcohol and Alcoholism Vol. 46, No. 3, pp. 312–317, 2011 doi: 10.1093/alcalc/agr017)
XVIII. Hamilton M.The assessment of anxiety states by rating. Br J Med Psychol 1959; 32:50–55.
XIX. Hamilton, M (1960) A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry. 23: 56–62
XX. Flannery BA, Volpicelli JR, Pettinati HM Psychometric properties of the Penn Alcohol Craving Scale Alcohol Clin Exp Res.1999 Aug;23(8):1289-95.
XXI. Manteghi AA, Hebrani P, Mortezania M et al. Baclofen add-on to citalopram in treatment of posttraumatic stress disorder. J Clin Psychopharmacol 2014;34:240–243.
XXII. WR Miller,Sanchez, VC. Motivating young adults for treatment and lifestyle change. In: Howard, G, ed. Issues in alcohol use and misuse by young adults. Notre Dame, IN: University of Notre Dame Press; 1993.
XXIII. Giovanni Addolorato Fabio Caputo Esmeralda Capristo Marco DomenicaliMauro Bernardi Luigi Janiri Roberta Agabio Giancarlo Colombo Gian Luigi GessaGiovanni Gasbarrini baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study alcohol and alcoholism, Volume 37, Issue 5, 1 September 2002, Pages 504–508
XXIV. Agabio R, Colombo G. GABAB receptor ligands for the treatment of alcohol use disorder: preclinical and clinical evidence. Front Neurosci 2014;8:140.
XXV. Anton RF, O’Malley SS, Ciraulo DA et al. COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006;295:2003–2017.
XXVI. Manushree Gupta, Pankaj Verma, Rajesh Rastogi, Sheetal Arora, Deeksha Elwadhi, Randomized open-label trial of baclofen for relapse prevention in alcohol dependence, The American Journal of Drug and Alcohol Abuse,2017,43(3):324-31.
XXVII. Addolorato G, Caputo F, Capristo et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomised controlled study. Alcohol 2002;37:504–508
XXVIII. Garbutt JC, Kampov-Polevoy AB, Gallop R et al. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res 2010;34:1849–1857.
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 International Education and Research Journal (IERJ)
This work is licensed under a Creative Commons Attribution 4.0 International License.
